Login:
Share:
Email Facebook Twitter

GWP Share Chat - RSS Feed

Gw Pharmaceuticals Share Chat (GWP)



Share Price: 344.00Bid: 343.75Ask: 345.00Change: 0.00 (0.00%)No Movement on Gw Pharm.
Spread: 1.25Spread as %: 0.36%Open: 308.00High: 351.75Low: 290.00Yesterday’s Close: 344.00


Share Discussion for Gw Pharm. (GWP)


Thread ViewThread View
Please Login or Register to post messages
Posts per page:


cashking
Posts: 7,618
Observation
Opinion:No Opinion
Price:80.00
MM DODGY DODGY
28 Dec '11
DODGY TRADES.
 
TheOptimist.
Posts: 40
Off Topic
Opinion:No Opinion
Price:82.00
Gwp
23 Dec '11
At a guess I would suggest that BSbob is at it again!!
Ddug
Posts: 2,591
Question
Opinion:No Opinion
Price:82.00
Gwp
23 Dec '11
Can anyone explain the bizarre selling activity going on this morning. can this be simply to hold down the price and if so it strikes me as a bit futile unless you have an infinite number of shares.
Crumbles
Posts: 58
Observation
Opinion:Strong Buy
Price:82.50
Swedish approval
22 Dec '11
I think this approval by Sweden knocks on the head an earlier post that some sort of anti-legalisation conspiracy is sabotaging this share. Sweden has one of the toughest prohibition regimes in the world as far the control of illicit substances is concerned, certainly the toughest in Europe. Any notion that Sativex is the thin end of a drug-legalisation wedge is now proven to be complete tosh. Long term holders of this stock should ignore the current fluctuations and continue looking north.
mulledwine
Posts: 35,667
Observation
Opinion:No Opinion
Price:78.50
GWP
22 Dec '11
Justin Gover, GW's Managing Director, said, "We are very pleased to announce the approval of Sativex® in Sweden. Sativex® addresses a significant unmet need for people with multiple sclerosis and we look forward to the launch of this important medicine in Sweden next year."

Sativex®, which has been developed by GW Pharmaceuticals, is also in phase III clinical development for the treatment of cancer pain, as the next indication following MS spasticity. Almirall holds the marketing rights to this medicine in Europe (except the United Kingdom).
mulledwine
Posts: 35,667
Observation
Opinion:No Opinion
Price:78.50
gwp
22 Dec '11
Sativex® approved in Sweden for the treatment of spasticity due to Multiple Sclerosis (MS)

Porton Down, UK; 22nd December 2011: GW Pharmaceuticals plc (AIM:GWP) today announced that the Medical Products Agency in Sweden has granted regulatory approval for Sativex® (Delta-9-Tetrahydro-cannabinol (THC) and Cannabidiol (CBD)) oromucosal spray as a treatment of moderate to severe spasticity due to MS in patients who have not responded adequately to other anti-spasticity medicationi. Sativex® is a first in class endocannabinoid system modulator and is currently available in the UK, Germany, Spain and Denmark.

Evidence generated from clinical trials shows that Sativex® has a positive impact on spasticity in multiple sclerosis, while alleviating associated symptoms including pain, bladder or sleep disturbance. By relieving the symptoms of MS, Sativex® can improve patients' quality of life and allow them greater independence in performing their daily activitiesii.

The launch of Sativex® in Sweden is expected to take place during the first half of 2012 following completion of the national pricing and reimbursement process. Sativex® will be marketed in Sweden by GW's marketing partner, Almirall S.A.
mulledwine
Posts: 35,667
Observation
Opinion:No Opinion
Price:78.50
GWP
22 Dec '11
cashking
Posts: 7,618
Observation
Opinion:No Opinion
Price:78.50
78.5p
21 Dec '11
what a joke, mm having a laugh here. ripping punters off. t
Ddug
Posts: 2,591
Observation
Opinion:No Opinion
Price:83.00
Phase 3
20 Dec '11
Final results expected late 2013 not early 2012 I think. Until gwp start making substantial profits what is going to move this one skywards?
TheOptimist.
Posts: 40
Off Topic
Opinion:No Opinion
Price:84.00
GWP
20 Dec '11
PEACE,LOVE and everlasting PATIENCE!!



Share Trading BrochureRequest your Free brochures on share dealing, spread betting and CFDs

Sign up for Live Prices


Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.